Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil, and Leucovorin Versus Oxaliplatin, 5-Fluorouracil, Leucovorin, and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation: A Trial of the ECOG-ACRIN Research Group (E5204)

A. Bapsi Chakravarthy, Fengmin Zhao, Neal J. Meropol, Patrick J. Flynn, Lynne I. Wagner, Jeffrey Sloan, Robert B. Diasio, Edith P. Mitchell, Paul Catalano, Bruce J. Giantonio, Robert B. Catalano, Daniel G. Haller, Rashid A. Awan, Mary F. Mulcahy, Timothy E. O'Brien, Roger Santala, Christine Cripps, John R. Weis, James N. Atkins, Cynthia G. LeichmanNicholas J. Petrelli, Frank A. Sinicrope, James D. Brierley, Joel E. Tepper, Peter J. O'Dwyer, Elin R. Sigurdson, Stanley R. Hamilton, David Cella, Al B. Benson

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Fingerprint

Dive into the research topics of 'Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil, and Leucovorin Versus Oxaliplatin, 5-Fluorouracil, Leucovorin, and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation: A Trial of the ECOG-ACRIN Research Group (E5204)'. Together they form a unique fingerprint.

Medicine & Life Sciences